BioSpace News Archive

2seventy bio, Inc., a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share.

Travere Therapeutics, Inc. announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant.

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2022.

VYNE Therapeutics Inc. announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on February 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules.

RxSight, Inc. announced plans to participate in the upcoming Oppenheimer Healthcare Conference.

PMV Pharmaceuticals, Inc. announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March.

Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the fourth quarter and year ended December 31, 2022.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its fourth quarter ended December 31, 2022 and provided its outlook on business performance for 2023.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the fourth quarter and full year ended December 31, 2022.